A5053168505- Immunotherapy and Immune Responses
- vaccines and immunoinformatics approaches
- T-cell and B-cell Immunology
- CAR-T cell therapy research
- Immune Cell Function and Interaction
- Cancer Immunotherapy and Biomarkers
- Glycosylation and Glycoproteins Research
- Galectins and Cancer Biology
- Monoclonal and Polyclonal Antibodies Research
- RNA Interference and Gene Delivery
- Toxin Mechanisms and Immunotoxins
- T-cell and Retrovirus Studies
- Virus-based gene therapy research
- Cancer Research and Treatments
- Hemophilia Treatment and Research
- Immune cells in cancer
- Cancer Genomics and Diagnostics
- Ubiquitin and proteasome pathways
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Platelet Disorders and Treatments
- Cellular transport and secretion
- Signaling Pathways in Disease
- Peptidase Inhibition and Analysis
- Vector-borne infectious diseases
- Cytomegalovirus and herpesvirus research
de Duve Institute
2015-2025
Walloon Excellence in Lifesciences and Biotechnology
2014-2025
UCLouvain
2012-2024
Ludwig Cancer Research
2008-2018
Bristol-Myers Squibb (Germany)
2017
Phio Pharmaceuticals (United States)
2017
Cliniques Universitaires Saint-Luc
2005-2014
Vrije Universiteit Brussel
2010-2014
Grand Charleroi Hospital
2010-2014
Imperial College London
2012
Many human melanoma tumors express antigens that are recognized in vitro by cytolytic T lymphocytes (CTLs) derived from the tumor-bearing patient. A gene was identified directed expression of antigen MZ2-E on a cell line. This shows no similarity to known sequences and belongs family at least three genes. It is expressed original cells, other lines, some tumor cells histological types. No observed panel normal tissues. Antigen appears be presented HLA-A1; anti-MZ2-E CTLs patient two lines...
Thirty-nine tumor-bearing patients with metastatic melanoma were treated 3 subcutaneous injections of the MAGE-3.A1 peptide at monthly intervals. No significant toxicity was observed. Of 25 who received complete treatment, 7 displayed tumor regressions. All but one these regressions involved cutaneous metastases. Three and 2 led to a disease-free state, which persisted for more than years after beginning treatment. evidence cytolytic T lymphocyte (CTL) response found in blood 4 analyzed,...
Human melanoma cell line MZ2-MEL expresses several antigens recognized by autologous cytolytic T lymphocyte (CTL) clones. We reported previously the identification of a gene, named MAGE-1, that codes for one these MZ2-E. show here antigen MZ2-D, which is present on same tumor, encoded another member MAGE gene family MAGE-3. Like MAGE-3 composed three exons and large open reading frame entirely located in third exon. Its sequence shows 73% identity with MAGE-1. MZ2-E, MZ2-D presented HLA-A1....
We have reported the identification of human gene MAGE-1, which directs expression an antigen recognized on a melanoma by autologous cytolytic T lymphocytes (CTL). show here that CTL directed against this antigen, was named MZ2-E, recognize nonapeptide encoded third exon MAGE-1. The also peptide when it is presented mouse cells transfected with HLA-A1 gene, confirming association MZ2-E molecule. Other members MAGE family do not code for same peptide, suggesting only MAGE-1 produces...
Abstract The human MAGE‐3 gene is expressed in many tumors of several histological types but it silent normal tissues, with the exception testis. Antigens encoded by may, therefore, be useful targets for specific anti‐tumor immunization cancer patients. We reported previously that codes an antigenic peptide recognized on a melanoma cell line autologous cytolytic T lymphocytes (CTL) restricted HLA‐A1. Here we report also another CTL HLA‐A2. peptides bearing consensus anchor residues HLA‐A2...
Purpose Adoptive transfer of genetically modified T cells is being explored as a treatment for patients with metastatic cancer. Most current strategies use genes that encode major histocompatibility complex (MHC) class I–restricted T-cell receptors (TCRs) or chimeric antigen to modify CD8 + bulk treatment. Here, we evaluated the safety and efficacy an adoptive CD4 therapy using MHC II–restricted, HLA-DPB1*0401–restricted TCR recognized cancer germline antigen, MAGE-A3 (melanoma-associated...
CD8 T lymphocytes recognize peptides of 8 to 10 amino acids presented by class I molecules the major histocompatibility complex. Here, were found a nonameric peptide on melanoma cells that comprises two noncontiguous segments melanocytic glycoprotein gp100(PMEL17). The production this involves excision four and splicing fragments. This process was reproduced in vitro incubating precursor 13 with highly purified proteasomes. Splicing appears occur transpeptidation involving an acyl-enzyme...
Of the antigens recognized on human tumors by autologous cytolytic T lymphocytes, all those defined thus far have been identified melanoma or renal cell carcinoma. We report here identification of an antigen lymphocytes a squamous carcinoma oral cavity. The is encoded mutated form CASP-8 gene. This gene, also named FLICE MACH, codes for protease caspase-8, which required induction apoptosis through Fas receptor and tumor necrosis factor receptor-1. mutation, was found in cells but not normal...
MAGE-type genes are expressed by many tumors of different histological types and not normal cells, except for male germline which do express major histocompatibility complex (MHC) molecules. Therefore, the antigens encoded strictly tumor specific common to tumors. We describe here identification first MAGE-encoded epitopes presented leukocyte antigen (HLA) class II molecules CD4+ T lymphocytes. Monocyte-derived dendritic cells were loaded with a MAGE-3 recombinant protein used stimulate...
Abstract Human melanoma cell line MZ2‐MEL expresses several antigens recognized by autologous cytolytic T lymphocyte (CTL) clones. We reported previously the identification of a gene, named MAGE‐1, which codes for antigen MZ2‐E is presented HLA‐A1. Gene MAGE‐1 expressed in many tumors types but not normal tissues except testis. show here that gene directs expression another CTL on cells. This antigen, was MZ2‐Bb, consists MAGE‐1‐encoded peptide SAYGEPRKL bound to major histocompatibility...
An optimal anticancer vaccine probably requires the cooperation of both CD4(+) Th cells and CD8(+) CTLs. A promising tool in cancer immunotherapy is, therefore, genetic modification dendritic (DCs) by introducing coding region a tumor Ag, which antigenic peptides will be presented HLA class I II molecules. This can achieved linking Ag to II-targeting sequence an endosomal or lysosomal protein. In this study we compared efficiency targeting signals invariant chain, lysosome-associated...
Purpose To evaluate the toxicity, antitumoral effectiveness, and immunogenicity of repeated vaccinations with ALVAC miniMAGE-1/3, a recombinant canarypox virus containing minigene encoding antigenic peptides MAGE-3 168-176 MAGE-1 161-169 , which are presented by HLA-A1 B35 on tumor cells can be recognized cytolytic T lymphocytes (CTLs). Materials Methods The vaccination schedule comprised four sequential injections virus, followed three booster peptides. vaccines were administered, both...